Coronavirus Disease 2019 (COVID-19) Sector Forecast: Analyst Consensus Sales Forecast
This report contains a summary of the analyst consensus forecasts available in the It Pharma Intelligence Center Drug Sales and Analyst Consensus Database for the Indication COVID-19. Despite the rapid development of COVID-19 therapies being developed the majority of the COVID-19 pipeline is in early stage development so there are few forecasts available. Currently there are three drugs indicated for COVID-19 which have analyst consensus forecasts available.
Scope
This 27-page report gives important, expert insight you wont find in any other source. 7 figures throughout the report illustrate major points and trends in COVID sales forecasts and company pipelines. This report is required reading for -
- Investors that want to understand how COVID-19 has impacted Drug Revenues in the biopharmaceutical industry as well as identifying companies to invest in
- Companies that are interested in entering the COVID-19 disease space
- Large pharma companies with investment groups or BD teams looking for partnership opportunities in the COVID-19 disease space
Reasons to Buy
- Analysis of COVID-19 analyst consensus sales forecasts
- Overview of Pipeline portfolio of companies involved in COVID-19 disease space
- Detailed Analysis of how COVID-19 have affected analyst consensus sales forecasts for previously forecasted Drugs
1 COVID-19 Global Analyst Consensus Sales Forecast
2 Gilead Sciences Inc.
2.1 Gilead Sciences Pipeline
2.2 Global Analyst Consensus Sales Forecast - Gilead Sciences Remdesivir
3 CanSino Biologic Inc.
3.1 CanSino Biologic Pipeline
3.2 Global Analyst Consensus Sales Forecast - CanSino Biologics COVID-19 Vaccine
4 Cytodyn Inc.
4.1 Global Analyst Consensus Sales Forecast - Cytodyns Leronlimab
4.2 Archived Global Analyst Consensus Sales Forecast - Cytodyns Leronlimab
5 Key Findings
6 Appendix
6.1 Methodology
6.2 Related Reports
6.3 About the Authors
6.4 About GlobalData
6.5 Contact Us
Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2021 Update
Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2021 UpdateThis 62-page PowerPoint based report gives an important update to the previous year with an expert analysis on how COVID-19 is
USD 1495 View ReportCoronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer - September 15, 2021
Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer - September 15, 2021When faced with an outbreak of a pathogen with no known treatments, we are forced to rely on the
USD 2495 View ReportCoronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2021 Update
Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2021 UpdateThis 62-page PowerPoint based report gives an important update to the previous year with an expert analysis on how COVID-19 is
USD 1495 View ReportCoronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer - September 15, 2021
Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer - September 15, 2021When faced with an outbreak of a pathogen with no known treatments, we are forced to rely on the
USD 2495 View ReportFill The Form For Sample Request